Too Much Cleavage of Cyclin E Promotes Breast Tumorigenesis


article has not abstract


Published in the journal: . PLoS Genet 8(3): e32767. doi:10.1371/journal.pgen.1002623
Category: Perspective
doi: 10.1371/journal.pgen.1002623

Summary

article has not abstract

Cyclin E, together with cyclin-dependent kinase 2 (CDK2), functions as a gatekeeper to promote G1/S transitions and the initiation of DNA replication. In normal cells, cyclin E–associated kinase activity is exquisitely regulated, with activity being limited to a brief time interval between late G1 and early S phase. Human cancers frequently exhibit deregulated cyclin E–associated kinase activity resulting from overexpression of cyclin E and loss of cyclin-dependent kinase inhibition (via p53 mutations) promoting genetic instability and cell proliferation [1]. Increased levels of cyclin E correlate with tumorigenesis and are a poor prognostic indicator independent of proliferation rate, suggesting that cyclin E's role in tumorigenesis is not limited to promoting increased cell proliferation [2], [3]. By eliminating regulatory constraints using p53 null cells, we and others have shown that overexpression or endogenous expression of stabilizing mutant forms of cyclin E can lead to hyperproliferation, genetic instability, and malignancy in cell culture and murine models [4], [5]. Normal cells suppress the effects of excess/stabilized cyclin E via the G1/S checkpoint involving the p53/p21 pathway.

Five isoforms of cyclin E, ranging in size from 33 to 44 kDa, have been identified in tumors over-expressing cyclin E. These low molecular weight forms of cyclin E (LMW-E) are generated through post-translational cleavage of full-length cyclin E by the elastase family of serine proteases in tumor cells [6], [7]. In comparison to full-length cyclin E (50 kDa), LMW-E forms are uniquely expressed in tumor cells, exhibit enhanced CDK2-associated kinase activity, have increased affinity for CDK2 [7][9], and exhibit decreased inhibition by CDK2 inhibitors, p21 and p27 (Figure 1) [10], [11]. Ectopic expression of LMW-E isoforms promotes cell proliferation, genetic instability, centrosome amplification, and malignancy [12], [13]. In addition, clinical studies have shown that high LMW-E is strongly associated with poor survival in breast cancer [2], colorectal cancer [14], [15], ovarian cancer [16], and melanomas [17]. Given its unique properties and distinct function in human cancers, targeting LMW-E could have important therapeutic implications.

Low molecular weight cyclin E promotes tumorigenesis.
Fig. 1. Low molecular weight cyclin E promotes tumorigenesis.
In normal cells, cyclin E/CDK2 is tightly regulated and triggers the onset of S phase. In tumors, cyclin E undergoes proteolytic processing generating low molecular weight species that exhibit increased kinase activity and resistance to inhibition by cyclin kinase inhibitors p21/p27. The expression of LMW-E promotes aberrant acinar morphogenesis, centrosome amplification, and tumors associated with activation of the bRaf/ERK/mTOR pathway. LMW-E, low molecular weight cyclin E.

The study by Duong et al. in this issue of PLoS Genetics [18] convincingly uncovers the tumorigenic potential of LMW-E. The authors used three different model systems—3D acinar cultures, xenograft transplantation, and transgenic mice—to show that overexpression of LMW-E is sufficient to induce aberrant acinar morphogenesis in culture and mammary tumors in mice (Figure 1). When grown on Matrigel, immortalized human mammary epithelial cells (hMECs) expressing LMW-E exhibit large misshapen multiacinar structures resulting from defective growth arrest and apoptosis that mimic morphologic features of breast carcinomas. Further, ectopic expression of LMW-E in immortalized hMECs promotes tumorigenesis in xenografts and transgenic mice to a much greater extent than full-length cyclin E. Consistent with the reports by Akli et al. and Nanos-Webb et al., tumorigenesis associated with LMW-E is dependent on CDK2 [19], [20]. Furthermore, in vivo passaging of tumor cells increases the expression of LMW-E, suggesting that LMW-E provides a selective growth advantage to the tumor. Duong et al. also took advantage of a proteomic analysis termed reverse-phase protein array assay (RPPA) to examine protein expression patterns in cultured tumor cells and in breast tumors expressing high LMW-E levels. Their analyses revealed that multiple components of the b-RAF-ERK1/2-mTOR pathway are elevated in these cells. Activation of the b-RAF-ERK1/2-mTOR pathway normally promotes cell division and cell survival. Consistent with this, the authors observed that endogenous cyclin E levels are also increased in cells expressing high LMW-E, indicative of the existence of a positive feedback loop that promotes cell proliferation. Both high LMW-E levels and up-regulation of the b-RAF-ERK1/2-mTOR signaling pathway are associated with poor survival, suggesting functional correlation of these events in aggressive tumors. Importantly, the authors demonstrated that combination therapy targeting LMW-E/CDK2 and the b-RAF-ERK1/2-mTOR pathway has a synergistic effect in abrogating the tumorigenic effect of LMW-E. Thus, the identification of these downstream regulators may provide novel biomarkers and/or potential therapeutic targets for LMW-E–expressing tumors.

The report that LMW-E potentiates tumorigenesis in three independent model systems associated with activation of the b-RAF-ERK1/2-mTOR pathway is intriguing. However, there are many important questions about the role of LMW-E in tumorigenesis that need to be addressed. 1) What is the functional relationship between LMW-E and full-length cyclin E? In each tumor model reported by Duong et al., the effect was examined by over-expressing LMW-E in a background of endogenous full-length cyclin E. Further, the authors show that ectopic expression of LMW-E in transplanted xenografts triggers tumor evolution and results in increased levels of endogenous cyclin E. Thus, the contribution of endogenous full-length cyclin E in tumorigenesis cannot be excluded. In addition, Spruck et al. reported that the level of LMW-E correlates with full-length cyclin E, suggesting that LMW-E reflects the total cyclin E protein in primary breast tumors, cell lines, and even normal breast tissue [21]. To examine the effect of LMW-E in the absence of over-expression, and in the absence of full-length cyclin E, it will be important to use a knock-in model in which expression of LMW-E is driven from the endogenous cyclin E promoter. 2) What is the relationship between LMW-E and the b-Raf-ERK1/2-mTOR signaling pathway? The authors demonstrated that the b-Raf-ERK1/2-mTOR signaling pathway is activated in tumors expressing high levels of LMW-E. The b-Raf-ERK1/2-mTOR pathway may be a downstream signaling pathway deregulated by LMW-E, or it could be a parallel survival pathway selected in LMW-E–expressing tumors. In particular, the fact that only combinational therapy targeting both cyclin E–associated kinase activity and the b-Raf-ERK1/2-mTOR pathway generates an anti-tumor effect argues against a direct cause–effect relationship and is suggestive of a parallel pathway. 3) Is LMW-E expression required for tumor growth and does down-regulation of LMW-E alter tumor growth, invasion, or metastasis? The authors have generated an inducible model that should facilitate these studies. 4) Is the tumor-promoting activity of LMW-E due to enhanced deregulated kinase activity or to alternative target specificity? The LMW-E construct used in these studies has an N-terminal deletion (40 amino acids) that eliminates the proposed nuclear localization signal (NLS) and potentially affects the intracellular localization and substrate specificity [22], [23]. 5) How is LMW-E generated in tumors, and is it tumor-type specific? It has been proposed and demonstrated by Caruso et al. that many tumors have elevated protease activity and decreased levels of protease inhibitors such as elafin [24] that may contribute to the generation of LMW-E. Further characterization of the proteolytic pathways that target cyclin E in tumors may provide alternative therapeutic targets.


Zdroje

1. HwangHCClurmanBE 2005 Cyclin E in normal and neoplastic cell cycles. Oncogene 24 2776 2786

2. KeyomarsiKTuckerSLBuchholzTACallisterMDingY 2002 Cyclin E and survival in patients with breast cancer. N Engl J Med 347 1566 1575

3. PorterPLMaloneKEHeagertyPJAlexanderGMGattiLA 1997 Expression of cell-cycle regulators p27Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nat Med 3 222 225

4. LoebKRKostnerHFirpoENorwoodTTsuchiyaKD 2005 A mouse model for cyclin E-dependent genetic instability and tumorigenesis. Cancer Cell 8 35 47

5. MinellaACSwangerJBryantEWelckerMHwangH 2002 p53 and p21 form an inducible barrier that protects cells against cyclin E-cdk2 deregulation. Curr Biol 12 1817 1827

6. HarwellRMPorterDCDanesCKeyomarsiK 2000 Processing of cyclin E differs between normal and tumor breast cells. Cancer Res 60 481 489

7. PorterDCZhangNDanesCMcGahrenMJHarwellRM 2001 Tumor-specific proteolytic processing of cyclin E generates hyperactive lower-molecular-weight forms. Mol Cell Biol 21 6254 6269

8. HarwellRMMullBBPorterDCKeyomarsiK 2004 Activation of cyclin-dependent kinase 2 by full length and low molecular weight forms of cyclin E in breast cancer cells. J Biol Chem 279 12695 12705

9. WingateHPuskasADuongMBuiTRichardsonD 2009 Low molecular weight cyclin E is specific in breast cancer and is associated with mechanisms of tumor progression. Cell Cycle 8 1062 1068

10. AkliSZhengPJMultaniASWingateHFPathakS 2004 Tumor-specific low molecular weight forms of cyclin E induce genomic instability and resistance to p21, p27, and antiestrogens in breast cancer. Cancer Res 64 3198 3208

11. WingateHZhangNMcGarhenMJBedrosianIHarperJW 2005 The tumor-specific hyperactive forms of cyclin E are resistant to inhibition by p21 and p27. J Biol Chem 280 15148 15157

12. AkliSVan PeltCSBuiTMultaniASChangS 2007 Overexpression of the low molecular weight cyclin E in transgenic mice induces metastatic mammary carcinomas through the disruption of the ARF-p53 pathway. Cancer Res 67 7212 7222

13. Bagheri-YarmandRBiernackaAHuntKKKeyomarsiK 2010 Low molecular weight cyclin E overexpression shortens mitosis, leading to chromosome missegregation and centrosome amplification. Cancer Res 70 5074 5084

14. ZhouYJXieYTGuJYanLGuanGX 2011 Overexpression of cyclin E isoforms correlates with poor prognosis in rectal cancer. Eur J Surg Oncol 37 1078 1084

15. CorinIDi GiacomoMCLastellaPBagnuloRGuantiG 2006 Tumor-specific hyperactive low-molecular-weight cyclin E isoforms detection and characterization in non-metastatic colorectal tumors. Cancer Biol Ther 5 198 203

16. DavidsonBSkredeMSilinsIShih IeMTropeCG 2007 Low-molecular weight forms of cyclin E differentiate ovarian carcinoma from cells of mesothelial origin and are associated with poor survival in ovarian carcinoma. Cancer 110 1264 1271

17. BalesEMillsLMilamNMcGahren-MurrayMBandyopadhyayD 2005 The low molecular weight cyclin E isoforms augment angiogenesis and metastasis of human melanoma cells in vivo. Cancer Res 65 692 697

18. DuongMTAkliSWeiCWingateHFLiuW 2012 LMW-E/CDK2 deregulates acinar morphogenesis, induces tumorigenesis and associates with the activated b-Raf-ERK1/2-mTOR pathway in breast cancer patients. PLoS Genet 8 e1002538 doi:10.1371/journal.pgen.1002538

19. AkliSVan PeltCSBuiTMeijerLKeyomarsiK 2011 Cdk2 is required for breast cancer mediated by the low-molecular-weight isoform of cyclin E. Cancer Res 71 3377 3386

20. Nanos-WebbAJabbourNAMultaniASWingateHOumataN 2011 Targeting low molecular weight cyclin E (LMW-E) in breast cancer. Breast Cancer Res Treat E-pub ahead of print 22 June 2011

21. SpruckCSunDFieglHMarthCMueller-HolznerE 2006 Detection of low molecular weight derivatives of cyclin E1 is a function of cyclin E1 protein levels in breast cancer. Cancer Res 66 7355 7360

22. DelkNAHuntKKKeyomarsiK 2009 Altered subcellular localization of tumor-specific cyclin E isoforms affects cyclin-dependent kinase 2 complex formation and proteasomal regulation. Cancer Res 69 2817 2825

23. JackmanMKubotaYden ElzenNHagtingAPinesJ 2002 Cyclin A- and cyclin E-Cdk complexes shuttle between the nucleus and the cytoplasm. Mol Biol Cell 13 1030 1045

24. CarusoJAHuntKKKeyomarsiK 2010 The neutrophil elastase inhibitor elafin triggers rb-mediated growth arrest and caspase-dependent apoptosis in breast cancer. Cancer Res 70 7125 7136

Štítky
Genetika Reprodukční medicína

Článek vyšel v časopise

PLOS Genetics


2012 Číslo 3

Nejčtenější v tomto čísle

Tomuto tématu se dále věnují…


Kurzy

Zvyšte si kvalifikaci online z pohodlí domova

Léčba bolesti v ordinaci praktického lékaře
nový kurz
Autoři: MUDr. PhDr. Zdeňka Nováková, Ph.D.

Revmatoidní artritida: včas a k cíli
Autoři: MUDr. Heřman Mann

Jistoty a nástrahy antikoagulační léčby aneb kardiolog - neurolog - farmakolog - nefrolog - právník diskutují
Autoři: doc. MUDr. Štěpán Havránek, Ph.D., prof. MUDr. Roman Herzig, Ph.D., doc. MUDr. Karel Urbánek, Ph.D., prim. MUDr. Jan Vachek, MUDr. et Mgr. Jolana Těšínová, Ph.D.

Léčba akutní pooperační bolesti
Autoři: doc. MUDr. Jiří Málek, CSc.

Nové antipsychotikum kariprazin v léčbě schizofrenie
Autoři: prof. MUDr. Cyril Höschl, DrSc., FRCPsych.

Všechny kurzy
Kurzy Doporučená témata Časopisy
Přihlášení
Zapomenuté heslo

Nemáte účet?  Registrujte se

Zapomenuté heslo

Zadejte e-mailovou adresu se kterou jste vytvářel(a) účet, budou Vám na ni zaslány informace k nastavení nového hesla.

Přihlášení

Nemáte účet?  Registrujte se